ArticleFrontiers in microbiology2023
Genomic characterization of vancomycin-resistant
Article in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 14 citations in OpenAlex.
- Genomic Epidemiology, Antimicrobial Resistance, and Virulence of ClinicalAntibiotics (Basel, Switzerland) · 2026Article
- Genomic investigation of the vancomycin-resistant Enterococcus faecium in a tertiary hospital in China.Antimicrobial resistance and infection control · 2026Article
- Article
- Article
- Article
- Pubescine as a Novel Antibacterial Agent Against Vancomycin-resistant Enterococcus: Growth Inhibition, Antibiotic Synergy, and Anti-biofilm Activity.Current pharmaceutical biotechnology · 2026Article
- Critical genomic insights into vancomycin-resistantMicrobiology spectrum · 2025Article
- Isolation ofAntibiotics (Basel, Switzerland) · 2025Article
- High-Risk VREfm Clones and Resistance Determinants in a Thai Hospital.Antibiotics (Basel, Switzerland) · 2025Article
- Clinical, genomic, and functional characterization of vancomycin-resistantFrontiers in cellular and infection microbiology · 2025Article
- A novel multidrug-resistantNew microbes and new infections · 2024Article
- Molecular Characterization of Enterococcus faecium Clinical Isolates Harbouring erm (T) from an Italian Hospital.Current microbiology · 2024Article
- Genomic Analysis of Antimicrobial Resistance inMicroorganisms · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vancomycin-resistant Enterococci (VREs) have increasingly become a major nosocomial pathogen worldwide, earning high-priority category from the World Health Organization (WHO) due to their antibiotic resistance. Among VREs, vancomycin-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.